A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.

Elena Garralda, Pilar Garrido, Javier García-Corbacho et al.|Journal of Clinical Oncology|2024

Cited by 2